Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Tocilizumab (RoActemra) as Early Treatment of Patients Affected by SARS-CoV2 (COVID-19) Infection With Severe Multifocal Interstitial Pneumonia

NCT04315480 is registered in ClinicalTrials.gov with Università Politecnica delle Marche as lead sponsor.

NCT NCT04315480
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04315480 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Tocilizumab (RoActemra) as Early Treatment of Patients Affected by SARS-CoV2 (COVID-19) Infection With Severe Multifocal Interstitial Pneumonia
Lead sponsor
Università Politecnica delle Marche
Phase
Phase 2
Overall status
Unknown status
Start date
March 12, 2020
Completion date
May 31, 2020
Enrollment
38 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

sars pneumonia